CheckMate 143 (NCT02017717), a large phase III randomised clinical trial evaluating PD-1 pathway inhibitors in GBM, enrolled 369 patients and compared the PD-1 monoclonal antibody nivolumab monotherapy with bevacizumab in the treatment of first relapsed disease. The gene discussed is PDCD1; the disease is glioblastoma.